global pulmonary drug delivery systems market is currently growing due to the increased prevalence of respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma.
The research study cites a report by the World Health Organization which says that there are currently 300 million people around the world who suffer from asthma and 210 million who suffer from COPD. The WHO also wrote that changing lifestyles and a growing habit of smoking tobacco are the prime causes of the heavy increase in respiratory diseases.The global pulmonary drug delivery systems market is divided into three major segments according to products: nebulizers, dry powder inhalers, and metered dose inhalers. The 2012 global pulmonary drug delivery systems market was dominated by metered dose inhalers, which held 56.8% of the market share. This segment was followed by dry powder inhalers.
The report says that the global demand for metered dose inhalers is expected to remain steady within its forecast period. It also says that nebulizers are expected to constitute the fastest growing segment in the forecast period. The demand for metered dose inhalers will be affected by a rising demand for the dry powder segment.The report’s geographical segmentation and analysis reveals that North America dominated the global pulmonary drug delivery systems market in 2012. The prime factor for the region’s growth was determined to be the high population that was affected by COPD and asthma in the U.S., coupled with the consistent awareness development programs held by the nation’s government and a firmly established healthcare reimbursement scenario.
Europe is expected to show a low CAGR in the global pulmonary drug delivery systems market due to government austerity measures and increasing penetration of generic drug makers.The report says that the Asia Pacific pulmonary drug delivery systems market is expected to grow due to the increasing number of people who smoke tobacco. The market’s growth is further augmented by rising healthcare expenditure and a growing level of awareness.
The report portrays a competitive global pulmonary drug delivery systems market in which the key players employ constant innovativeness to maintain and upgrade market positions. The list of top companies that the report examines includes PARI Respiratory Equipment Inc., CareFusion Corporation, 3M Health Care, Novartis AG, Omron Healthcare, Inc., Philips Respironics, Inc., and GlaxoSmithKline plc.